Unsolved problems in haemophilia

L. M. Aledort

Research output: Contribution to journalArticlepeer-review

23 Scopus citations

Abstract

Diagnosis and therapy for the vast majority of haemophiliacs in the world remain beyond their reach. Health care costs for hemophilia replacement products keep rising. Global inequities for financing health care result in most hemophiliacs being undertreated. The transfusion-transmitted disease, factor VIII inhibitors, is common. Its predictability escapes detection. Management has progressed substantially and offers many therapeutic modalities. Programs for prophylaxis or immune tolerance induction are impossible for most patients. Thus, the challenge for haemophiliacs is to attain these goals.

Original languageEnglish
Pages (from-to)341-345
Number of pages5
JournalHaemophilia
Volume4
Issue number4
DOIs
StatePublished - 1998

Keywords

  • APCC
  • Developing world
  • Health care costs
  • Inhibitors
  • PCC
  • Porcine VIII
  • Prophylaxis
  • rVIIa

Fingerprint

Dive into the research topics of 'Unsolved problems in haemophilia'. Together they form a unique fingerprint.

Cite this